Pershing Edward 4

4 · PROVECTUS BIOPHARMACEUTICALS, INC. · Filed Apr 29, 2026

AI-generated summary of this filing

Updated Apr 29, 2026

Provectus (PVCT) CEO Pershing Edward Converts Note, Acquires 30,202 Preferred

What Happened

Pershing Edward (CEO, Director) converted a 2025 unsecured convertible promissory note into 30,202 shares of Series D‑1 Convertible Preferred Stock on April 29, 2026. The Form 4 reports the derivative acquisition at $0.00 (transaction code M — exercise/conversion), but the conversion terms reference an implied price of $2.862 per Series D‑1 share, implying roughly $86,400 of note principal/interest was converted.
The filing also shows a related derivative disposition entry (N/A shares @ $0.00) consistent with converting the promissory note into preferred shares. This transaction is an acquisition of preferred stock via debt conversion rather than an open‑market purchase or sale.

Key Details

Date: April 29, 2026 (filing date matches transaction date)
Transaction type/code: Conversion of derivative / exercise (Code M)
Shares acquired: 30,202 shares of Series D‑1 Convertible Preferred Stock
Implied conversion price: $2.862 per Series D‑1 share → implied total ≈ $86,438
Shares owned after transaction: Not specified in the supplied filing summary
Notable footnotes:
- F1: Each Series D‑1 preferred share is convertible into 10 shares of common stock (so 30,202 preferred → potential 302,020 common shares upon conversion).
- F2: Series D‑1 will automatically convert into common stock on December 31, 2028 unless earlier converted per the Certificate of Designation.
- F3/F4: The 2025 Note could be voluntarily converted at $2.862/share and automatically converted 12 months after issuance; the 2025 Note was converted into the 30,202 Series D‑1 shares on 4/29/2026.

Context

This was a debt-to-equity conversion (note converted into preferred stock). The Form 4 shows $0.00 because the transaction reflects conversion of debt rather than a cash purchase; the filing’s footnotes provide the applicable conversion price.
Each preferred share converts into 10 common shares, so the preferred holding materially leverages possible common‑share exposure if/when converted.
No indication in the provided information that the filing was late.

Form 4

Period: 2026-04-29

DirectorCEO10% Owner

Transactions

Exercise/Conversion
8% Unsecured Convertible Promissory Note
[F3][F4]
2026-04-29
Exercise: $2.86From: 2025-04-29Exp: 2026-04-29→ Series D-1 Convertible Preferred Stock (30,202 underlying)
Exercise/Conversion
Series D-1 Convertible Preferred Stock
[F1][F2]
2026-04-29+30,202→ 2,774,233 total
From: 2026-04-29→ Common Stock (302,020 underlying)

Footnotes (4)

[F1]Each share of Series D-1 Preferred Stock is convertible into 10 shares of the Issuer's common stock, par value $0.001 per share ("Common Stock").
[F2]The Series D-1 Convertible Preferred Stock will automatically convert into Common Stock on December 31, 2028, unless earlier converted into Common Stock in accordance with the terms of the Certificate of Designation for the Series D-1 Convertible Preferred Stock.
[F3]The Reporting Person could have voluntarily elected to convert the outstanding principal and interest of the 8% unsecured convertible promissory note (the "2025 Note") at any time while the 2025 Note was outstanding into shares of Series D-1 Convertible Preferred Stock at a price per share equal to $2.862. The outstanding principal and interest of the 2025 Note automatically converted into shares of Series D-1 Preferred Stock at a price per share equal to $2.862 on the date which is twelve months after the issue date of the 2025 Note. The 2025 Note was issued pursuant to the Issuer's 2025 Financing.
[F4]On April 29, 2026, the 2025 Note was converted into 30,202 shares of Series D-1 Preferred Stock.

Signature

/s/ Edward Pershing|2026-04-29

1 file